A DOSIMETRY SYSTEM FOR IR-192 INTERSTITIAL BREAST IMPLANTS PERFORMED AT THE TIME OF LUMPECTOMY

Citation
Fm. Waterman et al., A DOSIMETRY SYSTEM FOR IR-192 INTERSTITIAL BREAST IMPLANTS PERFORMED AT THE TIME OF LUMPECTOMY, International journal of radiation oncology, biology, physics, 37(1), 1997, pp. 229-235
Citations number
10
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
ISSN journal
03603016
Volume
37
Issue
1
Year of publication
1997
Pages
229 - 235
Database
ISI
SICI code
0360-3016(1997)37:1<229:ADSFII>2.0.ZU;2-5
Abstract
Purpose: Ir-192 interstitial breast implants performed at the time of lumpectomy present a unique problem because they cannot be preplanned, and yet they are expected to produce a treatment dose rate (TDR) from 0.3 to 0.5 Gy/h using sources already procured, The purpose of this w ork is to describe a system of dosimetry that works within these const raints and has been used to perform more than 600 such implants. Metho ds and Materials: The underlying principle is to fix the ribbon spacin g, the interplaner separation, and the linear activity (1 mCi/cm) so t hat the TDR will depend only on the area (L x W) implanted, The ribbon s are spaced 1.5 cm and 2.0 cm apart in single plane and double implan ts, respectively, Idealized implants were used to study the TDR as a f unction of the implant dimensions, and to study the effects of varying the ribbon spacing and interplanar separation, Volume-dose histograms were generated to study the homogeneity of dose. Results: The TDRs of single plane implants range from 0.3 Gy/h for small 4 x 4 cm(2) impla nts to 0.4 Gy/h for large 10 x 10 cm(2) implants, The TDRs for double plane implants are similar for the same range of dimensions. Conclusio ns: Implants with a TDR between 0.3 and 0.5 Gy/h can be performed for a wide range of geometries without preplanning using fixed ribbons spa cings of 1.5 and 2.0 cm for single and double plane implants, respecti vely, and a linear activity of 1 mCi/cm. Copyright (C) 1997 Elsevier S cience Inc.